Colorectal Cancer With Liver Metastases Clinical Trial
Official title:
A Single-centre, Prospective, Cohort Trial of the Detection of 5-hydroxymethylcytosine (5-hmC) in Plasma Cell-free DNA for Establishing a Model for Predicting the Efficacy of Conversion Therapy for Patients With Unresectable Colorectal Cancer Liver Metastases
In this study, the investigators establish a model for predicting the efficacy of conversion therapy for the patients with unresectable liver metastases of colorectal cancer based on the detection of 5-hydroxymethylcytosine (5-hmC) in training group and validate the effectiveness of the model using a validation group.
Radical resection is the preferred treatment of colorectal cancer patients with liver
metastasas which significantly reduce the survival. However, the majority of the patients
cannot receive liver lesions resection resulting from the size, number and bad location.
Conversion therapy can improve the resection rate of these patients. Unfortunately, the
efficacy of conversion therapy is still poor in part of the patients. So, it is crucial to
distinguish the beneficial ones from the others.
The aim of this single center study is to establish a model for predicting the efficacy of
conversion therapy for the patients with unresectable liver metastases of colorectal cancer
based on the detection of 5-hmC. Patients will be eligible for inclusion if they suffer with
unresectable liver metastases of colorectal cancer and have not received any anti-tumor
treatment. Eligible patients will be assigned to effective group (group A) and drug
resistance group (group B) according to the evaluation results of multidisciplinary team
after 4-8 cycles of conversion therapy about 2-4 months.
Then, 5-hmC in plasma cell-free DNA will be detected and compared between the two groups of
patients (training group) to establish a model to predict the efficacy of convertion therapy
of other individuals (validation group) who suffer with unresectable liver metastases of
colorectal cancer receiving conversion therapy.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05268549 -
Independent Risk Factors Analysis and Model Construction For Recurrence After Radiofrequency/Microwave Ablation of Colorectal Cancer With Liver Metastases: a Retrospective, Multicenter Trial
|